{"product_id":"clinical-endocrine-oncology-isbn-9781405145848","title":"Clinical Endocrine Oncology","description":"\u003cb\u003eA truly comprehensive reference for the management of patients with endocrine cancer\u003c\/b\u003e\u003cbr\u003e \u003cp\u003eThe new edition of \u003ci\u003eClinical Endocrine Oncology\u003c\/i\u003e has been fully revised and extended making it the most comprehensive and up-to-date reference available. Written and edited by leading international experts in the field, it sets the standard in multidisciplinary care for patients with endocrine tumors.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eThe book provides specific and detailed guidance on the basic, clinical, investigative and therapeutic processes required for the thorough evaluation of a patient with a tumor in an endocrine organ. The eighty-four chapters are arranged in seven parts:\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e• Endocrine Oncology and Therapeutic Options\u003cbr\u003e • Thyroid and Parathyroid Tumors\u003cbr\u003e • Pituitary and Hypothalamic Lesions\u003cbr\u003e • Adrenal and Gonadal Tumors\u003cbr\u003e • Neuroendocrine Tumors and the Clinical Syndromes\u003cbr\u003e • Medical Syndromes and Endocrine Neoplasia\u003cbr\u003e • Endocrine-responsive Tumors and Female Reproductive Hormone Therapy.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eThis authoritative and practical text will be an invaluable resource for all those working in the field, including endocrinologists, medical oncologists, surgeons, radiation therapists, interventional radiologists, specialist nurses, and clinical scientists.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eJohn A.H. Wass is joined in this edition by a new editor, Ian D. Hay, Professor of Medicine and Endocrinology Research at the Mayo Clinic College of Medicine, Rochester, Minnesota, USA.\u003c\/p\u003e  List of Contributors. \u003cp\u003eForeword.\u003c\/p\u003e \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003eEndocrinology, the Hertz Brothers, and the History of Cancer.\u003c\/p\u003e \u003cp\u003ePart I: Endocrine Oncology and Therapeutic Options:.\u003c\/p\u003e \u003cp\u003e1 Structure and Development of the Endocrine System: John F. Morris (University of Oxford).\u003c\/p\u003e \u003cp\u003e2 Epidemiology of Endocrine Tumors: Amanda Nicholson (University College London).\u003c\/p\u003e \u003cp\u003e3 Inherited Cancers, Genes, and Chromosomes: Emma R. Woodward (Birmingham Women’s Hospital) and Eamonn R. Maher (Birmingham Women’s Hospital).\u003c\/p\u003e \u003cp\u003e4 Hormones, Growth Factors, and Tumor Growth: Andrew G. Renehan (Christie Hospital NHS Trust, Manchester).\u003c\/p\u003e \u003cp\u003e5 Genetic Counseling and Clinical Cancer Genetics: Lucy Side (Churchill Hospital, Oxford).\u003c\/p\u003e \u003cp\u003e6 Prospects for Gene Therapy for Endocrine Malignancies: Christine Spitzweg (Ludwig-Maximilians-University Munich), Ian D. Hay (Mayo Clinic, Rochester, USA), and John C. Morris (Mayo Clinic College of Medicine, Rochester, USA).\u003c\/p\u003e \u003cp\u003e7 Tumor Targeting: Mona Waterhouse (St Bartholomew’s Hospital, London) and Ashley B. Grossman (St Bartholomew’s Hospital, London).\u003c\/p\u003e \u003cp\u003e8 Techniques in Radiation Medicine: P. Nicholas Plowman (St Bartholomew’s Hospital, London).\u003c\/p\u003e \u003cp\u003e9 Interventional Radiology: Jane Phillips-Hughes (John Radcliffe Hospital, Oxford) and Philip Boardman (Churchill Hospital, Oxford).\u003c\/p\u003e \u003cp\u003e10 Surgical Management of Endocrine Tumors: Gustavo G. Fernandez Ranvier (University of California, San Francisco) and Orlo H. Clark (University of California, San Francisco).\u003c\/p\u003e \u003cp\u003e11 Endocrine Tumor Markers: Stefan K.G. Grebe (Mayo Clinic, Rochester).\u003c\/p\u003e \u003cp\u003e12 General Management of Cancer Patients: Marcia Hall (Mount Vernon Cancer Centre, Middlesex).\u003c\/p\u003e \u003cp\u003ePart II: Thyroid and Parathyroid Tumors:.\u003c\/p\u003e \u003cp\u003e13 Assessment of Thyroid Neoplasia: Kristien Boelaert (Queen Elizabeth Hospital, Birmingham), Jayne A. Franklyn (University of Birmingham), and Michael Sheppard (University of Birmingham).\u003c\/p\u003e \u003cp\u003e14 Thyroid and Parathyroid Imaging: Conor J. Heaney (Mayo School of Graduate Medical Education, Rochester, USA) and Gregory A. Wiseman (Mayo Clinic College of Medicine, Rochester, USA).\u003c\/p\u003e \u003cp\u003e15 Pathogenesis of Thyroid Cancer: Jan Zedenius (Karolinska University Hospital, Stockholm) and Theodoros Foukakis (Karolinska University Hospital, Stockholm).\u003c\/p\u003e \u003cp\u003e16 Papillary Thyroid Carcinoma: Ian D. Hay (Mayo Clinic, Rochester, USA).\u003c\/p\u003e \u003cp\u003e17 Follicular Thyroid Carcinoma: Manisha H. Shah (The Ohio State University) and Matthew D. Ringel (The Ohio State University).\u003c\/p\u003e \u003cp\u003e18 Anaplastic Thyroid Carcinoma: Richard T. Kloos (The Arthur G James Cancer Hospital and Solove Research Center, Columbus).\u003c\/p\u003e \u003cp\u003e19 Thyroid Lymphoma: Christopher M. Nutting (Royal Marsden Hospital, London) and Kevin J. Harrington (Cancer Research UK Centre for Cell and Molecular Biology, London).\u003c\/p\u003e \u003cp\u003e20 Radiation-induced Thyroid Tumors: David H. Sarne (University of Illinois at Chicago) and Arthur Schneider (University of Illinois at Chicago).\u003c\/p\u003e \u003cp\u003e21 Parathyroid Adenomas and Hyperplasia: Bart L. Clarke (Mayo Clinic College of Medicine, Rochester).\u003c\/p\u003e \u003cp\u003e22 Parathyroid Carcinoma: Göran Åkerström (University Hospital, Uppsala, Sweden), Per Hellman (University of Uppsala, Sweden), and Peyman Björklund (University of Uppsala, Sweden).\u003c\/p\u003e \u003cp\u003ePart III: Pituitary and Hypothalamic Lesions:.\u003c\/p\u003e \u003cp\u003e23 Molecular Pathogenesis of Pituitary Adenomas: Ines Donangelo (University of California Los Angeles) and Shlomo Melmed (University of California Los Angeles).\u003c\/p\u003e \u003cp\u003e24 Functional Assessment of the Pituitary: John S. Bevan (Aberdeen Royal Infirmary).\u003c\/p\u003e \u003cp\u003e25 Imaging of the Pituitary and Hypothalamus: James V. Byrne (John Radcliffe Hospital, Oxford).\u003c\/p\u003e \u003cp\u003e26 Pathology of Tumors of the Pituitary: Eva Horvath (St. Michael’s Hospital, Toronto) and Kalman Kovacs (St. Michael’s Hospital, Toronto).\u003c\/p\u003e \u003cp\u003e27 Surgery for Pituitary Tumors: Simon A. Cudlip (John Radcliffe Hospital, Oxford).\u003c\/p\u003e \u003cp\u003e28 Pituitary Radiotherapy: P. Nicholas Plowman (St Bartholomew’s Hospital, London).\u003c\/p\u003e \u003cp\u003e29 Prolactinomas: Mary P. Gillam (Northwestern University Feinberg School of Medicine, Chicago) and Mark E. Molitch (Northwestern University Feinberg School of Medicine, Chicago).\u003c\/p\u003e \u003cp\u003e30 Acromegaly: John A.H. Wass (Churchill Hospital, Oxford).\u003c\/p\u003e \u003cp\u003e31 Cushing’s Disease: John Newell-Price (University of Sheffield).\u003c\/p\u003e \u003cp\u003e32 Non-functioning Pituitary Adenomas and Gonadotropinomas: Maarten O. van Aken (Erasmus Medical Center, Rotterdam), Aart Jan van der Lelij (Erasmus Medical Center, Rotterdam), and Steven W.J. Lamberts (Erasmus Medical Center, Rotterdam).\u003c\/p\u003e \u003cp\u003e33 Thyrotropinomas: Paolo Beck-Peccoz (Fondazione Policlinico IRCCS, Milan) and Luca Persani (Istituto Auxologico Italiano IRCCS, Milan).\u003c\/p\u003e \u003cp\u003e34 Pituitary Carcinoma: Olaf Ansorge (John Radcliffe Hospital, Oxford).\u003c\/p\u003e \u003cp\u003e35 Pituitary Incidentalomas: Karin Bradley (Bristol Royal Infirmary).\u003c\/p\u003e \u003cp\u003e36 Craniopharyngioma: Niki Karavitaki (Churchill Hospital, Oxford).\u003c\/p\u003e \u003cp\u003e37 Benign Cysts: Rathke’s Cleft Cysts, Mucoceles, Arachnoid Cysts, and Dermoid and Epidermoid Cysts: Niki Karavitaki (Churchill Hospital, Oxford).\u003c\/p\u003e \u003cp\u003e38 Hypothalamic Hamartomas and Gangliocytomas: Lawrence A. Frohman (University of Illinois at Chicago).\u003c\/p\u003e \u003cp\u003e39 Cranial Ependymoma: Silvia Hofer (University Hospital Zürich) and Michael Brada (The Royal Marsden NHS Trust, London and Sutton).\u003c\/p\u003e \u003cp\u003e40 Perisellar Tumors including Chordoma, Optic Nerve Glioma, Meningioma, Hemangiopericytoma, and Glomus Tumors: David Choi (The National Hospital for Neurology and Neurosurgery, London) and Alan Crockard (The National Hospital for Neurology and Neurosurgery, London).\u003c\/p\u003e \u003cp\u003e41 Pineal Tumors: Germinomas and Non-germinomatous Germ Cell Tumors: Frank Saran (Royal Marsden NHS Foundation Trust, Sutton) and Sharon Peoples (Western General Hospital, Edinburgh).\u003c\/p\u003e \u003cp\u003e42 Cavernous Sinus Hemangiomas: Mark E. Linskey (University of California).\u003c\/p\u003e \u003cp\u003e43 Langerhans’ Cell Histiocytosis: Matthew F. Gorman (University of California), Michelle Hermiston (UCSF School of Medicine, San Francisco), and Katherine K. Matthay (UCSF School of Medicine, San Francisco).\u003c\/p\u003e \u003cp\u003e44 Pituitary and Hypothalamic Sarcoidosis: Damian G. Morris (The Ipswich Hospital NHS Trust) and Shern L. Chew (St Bartholomew’s Hospital, London).\u003c\/p\u003e \u003cp\u003ePart IV: Adrenal and Gonadal Tumors:.\u003c\/p\u003e \u003cp\u003e45 Imaging of the Adrenal Glands: Anju Sahdev (St Bartholomew’s Hospital, London) and Rodney H. Reznek (Barts and The London School of Medicine and Dentistry).\u003c\/p\u003e \u003cp\u003e46 Pheochromocytoma: Andrew Solomon (Royal Free Hospital, London) and Pierre Bouloux (Royal Free and University College Medical School, London).\u003c\/p\u003e \u003cp\u003e47 Peripheral Neuroblastic Tumors: Bruno De Bernardi (Giannina Gaslini Children’s Hospital), Vito Pistoia (Giannina Gaslini Children’s Hospital), Claudio Gambini (Giannina Gaslini Children’s Hospital), and Claudio Granata (Giannina Gaslini Children’s Hospital).\u003c\/p\u003e \u003cp\u003e48 Primary Hyperaldosteronism: Mark Sherlock (University of Birmingham) and Paul M. Stewart (University of Birmingham).\u003c\/p\u003e \u003cp\u003e49 Adrenal Causes of Cushing’s Syndrome: John R. Lindsay (Altnagelvin Area Hospital, Londonderry) and A. Brew Atkinson (Royal Victoria Hospital, Belfast).\u003c\/p\u003e \u003cp\u003e50 Adrenal Incidentalomas: Maria Verena Cicala (University of Padua), Pierantonio Conton (University of Padua), Anna Patalano (University of Padua), and Franco Mantero (University of Padua).\u003c\/p\u003e \u003cp\u003e51 Androgen-secreting Tumors: Quirinius Barnor (University College London Hospitals), Tom R. Kurzawinski (University College London Hospitals), and Gerard S. Conway (University College London Hospitals).\u003c\/p\u003e \u003cp\u003e52 Functional Ovarian Tumors: Nia Jane Taylor (The John Radcliffe Hospital, Oxford) and Niall Richard Moore (University of Oxford).\u003c\/p\u003e \u003cp\u003e53 Endocrine Aspects of Ovarian Tumors: John H. Shepherd (Royal Marsden Hospital, London) and Lisa Wong (Royal Marsden Hospital, London).\u003c\/p\u003e \u003cp\u003e54 Testicular Germ Cell Cancers: R. Timothy D. Oliver (St Bartholomew’s Hospital, London).\u003c\/p\u003e \u003cp\u003e55 Neoplasia and Intersex States: Sabine E. Hannema (Juliana Children’s Hospital, The Hague) and Ieuan A. Hughes (University of Cambridge).\u003c\/p\u003e \u003cp\u003e56 Gestational Trophoblastic Neoplasia: Tim Crook (Charing Cross Hospital) and Michael J. Seckl (Hammersmith Hospitals Campus of Imperial College London).\u003c\/p\u003e \u003cp\u003ePart V: Neuroendocrine Tumors and the Clinical Syndromes:.\u003c\/p\u003e \u003cp\u003e57 Classification of Neuroendocrine Tumors: Adeel Ansari (Hammersmith Hospital Campus, Imperial College London), Karim Meeran (Imperial College London), and Stephen R. Bloom (Imperial College London).\u003c\/p\u003e \u003cp\u003e58 Imaging of Gastrointestinal Neuroendocrine Tumors: Andrew F. Scarsbrook (St James’s University Hospital) and Rachel R. Phillips (University of Oxford).\u003c\/p\u003e \u003cp\u003e59 Insulinomas and Hypoglycemia: Adrian Vella (Mayo Clinic College of Medicine, Rochester, USA) and F. John Service (Mayo Clinic College of Medicine, Rochester, USA).\u003c\/p\u003e \u003cp\u003e60 Gastrinomas (Zollinger–Ellison Syndrome): Matthew L. White (St. Joseph Mercy Hospital, Ann Arbor, Michigan) and Gerard M. Doherty (University of Michigan).\u003c\/p\u003e \u003cp\u003e61 VIPomas: Vian Amber (Imperial College London) and Stephen R. Bloom (Imperial College London).\u003c\/p\u003e \u003cp\u003e62 Glucagonomas: Niamh M. Martin (Imperial College London), Karim Meeran (Imperial College London), and Stephen R. Bloom (Imperial College London).\u003c\/p\u003e \u003cp\u003e63 Somatostatinomas: John A.H. Wass (Churchill Hospital, Oxford).\u003c\/p\u003e \u003cp\u003e64 Lung and Thymic Neuroendocrine Tumors: Dan Granberg (University Hospital, Uppsala, Sweden) and Kjell Öberg (University Hospital, Uppsala, Sweden).\u003c\/p\u003e \u003cp\u003e65 Carcinoid Syndrome: Thorvardur R. Halfdanarson (Mayo Clinic College of Medicine, Rochester, USA) and Timothy J. Hobday (Mayo Clinic, Rochester, USA).\u003c\/p\u003e \u003cp\u003e66 Appendiceal and Hindgut Carcinoids: Humphrey J.F. Hodgson (Royal Free and University College School of Medicine, London).\u003c\/p\u003e \u003cp\u003e67 Chemotherapy for Neuroendocrine Tumors: Rebecca L. Bowen (St Bartholomew’s Hospital, London) and Maurice L. Slevin (St Bartholomew’s Hospital, London).\u003c\/p\u003e \u003cp\u003ePart VI: Medical Syndromes and Endocrine Neoplasia:.\u003c\/p\u003e \u003cp\u003e68 Multiple Endocrine Neoplasia Type 1 (MEN 1): Cornelis J.M. Lips (University Medical Center, Utrecht), Koen M.A. Dreijerink (University Medical Center, Utrecht), Gerlof D. Valk (University Medical Center, Utrecht), and Jo W.M. Höppener (University Medical Center Utrecht).\u003c\/p\u003e \u003cp\u003e69 Medullary Thyroid Carcinoma and Associated Multiple Endocrine Neoplasia Type 2: Clive S. Grant (Mayo Clinic, USA).\u003c\/p\u003e \u003cp\u003e70 von Hippel–Lindau Disease: Shern L. Chew (St Bartholomew’s Hospital, London) and Eamonn R. Maher (University of Birmingham School of Medicine).\u003c\/p\u003e \u003cp\u003e71 Neurofibromatosis Type 1: Vincent M. Riccardi (The Neurofibromatosis Institute, California).\u003c\/p\u003e \u003cp\u003e72 Carney Complex: Constantine A. Stratakis (National Institutes of Health, USA).\u003c\/p\u003e \u003cp\u003e73 McCune–Albright Syndrome: William F. Schwindinger (Geisinger Clinic Danville, USA) and Michael A. Levine (Cleveland Clinic Children’s Hospital).\u003c\/p\u003e \u003cp\u003e74 Cowden Syndrome: Ingrid Witters (University Hospital of Leuven, Belgium) and Jean-Pierre Fryns (University Hospital of Leuven).\u003c\/p\u003e \u003cp\u003e75 Paraneoplastic Syndromes: David William Ray (University of Manchester).\u003c\/p\u003e \u003cp\u003e76 Syndrome of Inappropriate Antidiuretic Hormone Secretion: Rachel K. Crowley (Beaumont Hospital, Dublin) and Chris Thompson (Beaumont Hospital).\u003c\/p\u003e \u003cp\u003e77 Hypercalcemia of Malignancy: Gregory R. Mundy (Vanderbilt Center for Bone Biology, USA), Babatunde Oyajobi (University of Texas), Susan Padalecki (University of Texas),.\u003c\/p\u003e \u003cp\u003eand Julie A. Sterling (Vanderbilt University, USA).\u003c\/p\u003e \u003cp\u003e78 Syndrome of Ectopic ACTH Secretion: Marie-Laure Raffin-Sanson (Hôpital Ambroise Paré, Boulogne, France), Hélène Fierrard (Hôpital Ambroise Paré, Boulogne, France),.\u003c\/p\u003e \u003cp\u003eand Xavier Bertagna (Université Paris Descartes, France).\u003c\/p\u003e \u003cp\u003e79 Insulin-like Growth Factors and Tumor Hypoglycemia: Robert C. Baxter (University of Sydney).\u003c\/p\u003e \u003cp\u003e80 Metastatic and Other Extraneous Neoplasms in Endocrine Organs: Ian D. Buley (Torbay Hospital, UK).\u003c\/p\u003e \u003cp\u003e81 Endocrine Late Effects of Cancer Therapy: Robert D. Murray (Leeds Teaching Hospitals NHS Trust).\u003c\/p\u003e \u003cp\u003ePart 7: Endocrine-responsive Tumors and Female Reproductive Hormone Therapy.\u003c\/p\u003e \u003cp\u003e82 Endocrine-responsive Tumors: Prostate Cancer: Sarah Ngan (Imperial College London), Ana Arance (Hammersmith Hospital, London), and Jonathan Waxman (Imperial College London).\u003c\/p\u003e \u003cp\u003e83 Endocrine Therapy in Breast Cancer Management: Andrew M. Wardley (Christie Hospital, Manchester).\u003c\/p\u003e \u003cp\u003e84 Female Reproductive Hormone Therapy: Risks and Benefits: Toral Gathani (University of Oxford), Jane Green (University of Oxford), and Valerie Beral (University of Oxford).\u003c\/p\u003e \u003cp\u003eAppendix of conversion units.\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e \u003cp\u003eColor plate section\u003c\/p\u003e  “I recommend the book for physicians who see diagnose and treat patients with endocrine tumors It provides a broad strong base of knowledge and a good foundation for further investigation of the treatment options for these tumors.” (\u003ci\u003eNew England Journal of Medicine\u003c\/i\u003e, April 2009)  \u003cp\u003e“The new edition of Clinical Endocrine Oncology has been fully revised and extended making it the most comprehensive and up-to-date reference available. Written and edited by leading international experts in the field, it sets the standard in multidisciplinary care for patients with endocrine tumors. This authoritative and practical text will be an invaluable resource for all those working in the field … .Because so much has changed since the first edition was published 11 years ago, a second edition is warranted.” (\u003ci\u003eDoody's Book Reviews\u003c\/i\u003e, October 2008)\u003c\/p\u003e  \u003cb\u003eIan D. Hay\u003c\/b\u003e, Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. A Glasgow graduate, Professor Hay has spent the majority of his career in the USA, winning the Randall G. Sprague Award for Outstanding Achievement as a Subspecialty Trainee in Endocrinology from the Mayo Clinic in 1981. He has been recognised with thirteen awards throughout his career, the latest one being the Prix de la Journee de Medecine Nucleaire from the l'Institut Gustave Roussy, Villejuif, France in 1997. He is also a contributor to Williams’ Textbook of Endocrinology.\u003cbr\u003e \u003cp\u003e\u003cb\u003eJohn A.H. Wass\u003c\/b\u003e, Professor of Endocrinology, The Oxford Centre for Diabetes, Endocrinology \u0026amp; Metabolism, Oxford, UK. Current President of the European Federation of Endocrine Societies and President of the Society for Endocrinology (UK). Co-Editor of The Oxford Textbook of Endocrinology and Diabetes (published 2002) and The Oxford Handbook of Endocrinology and Diabetes (published August 2002).\u003c\/p\u003e  \u003cb\u003eA truly comprehensive reference for the management of patients with endocrine cancer\u003c\/b\u003e\u003cbr\u003e \u003cp\u003eThe new edition of \u003ci\u003eClinical Endocrine Oncology\u003c\/i\u003e has been fully revised and extended making it the most comprehensive and up-to-date reference available. Written and edited by leading international experts in the field, it sets the standard in multidisciplinary care for patients with endocrine tumors.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eThe book provides specific and detailed guidance on the basic, clinical, investigative and therapeutic processes required for the thorough evaluation of a patient with a tumor in an endocrine organ. The eighty-four chapters are arranged in seven parts:\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e• Endocrine Oncology and Therapeutic Options\u003cbr\u003e • Thyroid and Parathyroid Tumors\u003cbr\u003e • Pituitary and Hypothalamic Lesions\u003cbr\u003e • Adrenal and Gonadal Tumors\u003cbr\u003e • Neuroendocrine Tumors and the Clinical Syndromes\u003cbr\u003e • Medical Syndromes and Endocrine Neoplasia\u003cbr\u003e • Endocrine-responsive Tumors and Female Reproductive Hormone Therapy.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eThis authoritative and practical text will be an invaluable resource for all those working in the field, including endocrinologists, medical oncologists, surgeons, radiation therapists, interventional radiologists, specialist nurses, and clinical scientists.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eJohn A.H. Wass is joined in this edition by a new editor, Ian D. Hay, Professor of Medicine and Endocrinology Research at the Mayo Clinic College of Medicine, Rochester, Minnesota, USA.\u003c\/p\u003e  \"\u003ci\u003eClinical Endocrine Oncology\u003c\/i\u003e fills a large void in the medical literature, since it is especially targeted to the treatment of patients with malignant endocrine tumors. . . . I recommend this book for physicians who see, diagnose, and treat patients with endocrine tumors. It provides a broad, strong base of knowledge and a good foundation for further investigation of the treatment options for these tumors.\"\u003cbr\u003e –Jeffrey A. Norton, MD, in a review in NEJM","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47988932411621,"sku":"NP9781405145848","price":430.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405145848.jpg?v=1761782104","url":"https:\/\/k12savings.com\/products\/clinical-endocrine-oncology-isbn-9781405145848","provider":"K12savings","version":"1.0","type":"link"}